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Delivery of cell therapies often requires the ability to hold products in 
readiness whilst logistical, regulatory and potency considerations are 
dealt with and recorded. This requires reversibly stopping biological time, 
a process which is often achieved by cryopreservation. However, cryo-
preservation itself poses many biological and biophysical challenges to liv-
ing cells that need to be understood in order to apply the low temperature 
technologies to their best advantage. This review sets out the history of 
applied cryopreservation, our current understanding of the various pro-
cesses involved in storage at cryogenic temperatures, and challenges for 
robust and reliable uses of cryopreservation within the cell therapy arena.  
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The explosion of interest in cell ther-
apies over recent years has necessarily 
focused attention on the processes 
that will enable product delivery in 
reliable, regulatory-compliant and 
robust ways. These considerations 
sometimes introduce new challeng-
es that may not have been import-
ant in the original laboratory studies 
on that particular cell therapy. One 
such consideration is product stor-
age (cryobanking), which is often 
required to sustain cell therapy de-
livery to the end user facilities at the 
required time, providing a quality 
assured product with required safe-
ty and potency characteristics [1,2]. 
Cryopreservation in its various forms 
is one of the main facilitatory tech-
nologies for cell therapies to be able 
to meet these demands. This brief 
review will discuss the salient top-
ics within this field and include the 
history of cryopreservation, what we 
currently understand about the bio-
physical and biological processes that 
allow successful cell recoveries after 
storage, and additional challenges 
for scale up and regulatory oversight 
when the technology is applied. 
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HISTORY OF 
CRYOPRESERVATION 
The widely accepted term to de-
scribe preservation of living cells, 
capable of biological reanimation, 
is cryopreservation. In reality, cell 
biopreservation can be achieved 
across a range of reduced tempera-
tures, which enhance survival by 
reducing biological activities, but 
with limitations dependent upon 
the chosen modality.  The common 
conception of cryopreservation is 
storage of living cells at the deep 
cryogenic temperatures provided by 
liquid nitrogen or the associated va-
pour phase (ranging from -196o to 
approximately -170oC). 
The challenge for biology of 
course is the phase change of wa-
ter that occurs at the rather in-
conveniently high temperature 
(for biopreservation purposes) just 
below 0oC. There have been many 
studies over the past few hundred 
years on the biological effects of 
freezing, and the allied phenome-
non of freeze tolerance in overwin-
tering species (most often in the 
plant kingdom). The growing un-
derstanding of freezing effects fol-
lowed the development of micro-
scopes capable of directly observing 
the freezing process; for example 
Molisch [3] described the freezing 
process in plant tissues, which im-
mediately highlighted one of the 
central problems with ice forma-
tion – the fact that ice, derived as 
the phase change of pure water, re-
sulted in exposure of the cells to a 
residual hypertonic environment as 
solutes (originally dissolved in the 
aqueous environment) are excluded 
from the ice crystal lattice. In simple 
terms, the cells experienced a lethal 
osmotic stress that could be detect-
ed at the structural level very quick-
ly after thawing. Other scientists of 
the same era, such as Maximov [4] 
provided evidence that in plants ca-
pable of overwintering in northern 
Russia, the tissues went through a 
seasonal hardening process, which 
was accompanied by accumulation 
of solutes such as sugars. Chambers 
and Hale [5] at the turn of the 20th 
Century provided additional evi-
dence from light microscope stud-
ies that there was an osmotic effect 
of freezing directly on the plant 
cells that was accompanied by lysis 
on thawing. Over the subsequent 
50 years, others continued to ex-
plore the biophysical principles 
and biological effects of the water–
ice phase transition; for example 
Luyet [6] made many pertinent ob-
servations on ice crystal structures, 
changes in these brought about by 
alterations in the kinetics of cool-
ing or the presence of solutes in 
the aqueous medium, and the ef-
fects on living cells. This collected 
knowledge base undoubtedly influ-
enced Polge [7] and his colleagues 
in their studies in 1949 on freezing 
of reproductive cells (notably fowl 
spermatozoa to enhance animal 
breeding in the period post the Sec-
ond World War) which resulted in 
the first clear evidence of recovery 
of functional cells after deliberate 
deep cryogenic exposure (in their 
case to -79oC using solid carbon 
dioxide – liquid nitrogen was not 
readily available at that time). The 
key to their success was the expo-
sure of the sperm to glycerol ahead 
of the cooling process, which Polge 
later acknowledged was partly by 
good fortune, but nevertheless (and 
with the benefit of hindsight), com-
bined all of those previous studies 
into one successful outcome. That 
success also fuelled a global effort 
to better understand and maxi-
mize the opportunities provided in 
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biology and medicine for extend-
ed biopreservation, culminating in 
the definition of the term ‘cryobi-
ology’ to encompass the necessary 
collaboration between biologists, 
engineers and physicists to better 
understand the processes, and the 
establishment of the International 
Society for Cryobiology in 1963.
CURRENT UNDERSTANDING 
OF CRYOPRESERVATION
The water–ice phase 
transition
As is universally accepted, liquid 
water is the essential component for 
almost all biological processes [8], 
and its removal during the forma-
tion of ice poses extreme challeng-
es. There have been many excellent 
reviews on this topic, but a decade 
ago Mazur [9] and Muldrew and 
colleagues [10] provided excellent 
discussions on the topic with spe-
cific relevance to cryobiology. These 
are beyond the remit of the current 
discussion, but as a brief summary, 
water exists in the liquid state in a 
random but self-associating matrix 
(on an extremely brief timescale) 
through interactions of hydrogen 
bonding, which for biology enables 
solvation of essential ions and sol-
utes, and structural stability of many 
macromolecules. During cooling, 
energy within the system is removed 
and water molecule self-association 
leads to longer-lived intermolecular 
connections that result in ice nuclei. 
In this process, central water mole-
cules hydrogen bond with four sur-
rounding others that at the point of 
freezing repeat indefinitely through-
out the aqueous milieu to yield hex-
agonal ice with which we are all fa-
miliar. The open lattice nature also 
results in the often observed slight 
change in density of ice over liquid 
water. The stabilisation of the net-
work also results in the well-known 
release of energy detectable as the 
latent heat of ice formation. The 
ice crystal lattice cannot maintain 
previously accommodated solutes, 
which become excluded into the 
residual liquid volume surrounding 
the growing ice interface, which in 
turn depresses the freezing point of 
the residual water so that cells are 
exposed to progressively higher sol-
utes in a progressively smaller liquid 
water space. Thus ‘freezing’ is not an 
instantaneous event in most practi-
cal applications, even though it may 
appear so to the naked eye. 
Residual mobile water, all-be-
it as a tiny fraction of the origi-
nal water volume, can be detected 
down to surprisingly low tempera-
tures [11], contributing to the pro-
gressive osmotic stress experienced 
by the cells. Multiple biological 
targets for this type of injury have 
been discussed, including destabil-
isation of cell membranes, change 
in the intracellular milieu includ-
ing pH, chemical and structural 
changes to organelles and to pro-
teins; it is fair to say that we still 
do not fully understand all the bi-
ological consequences [9,10]. What 
is clear is that in almost all cases, 
cell membranes and intracellular 
macromolecules to some degree 
hinder the kinetics of the forma-
tion of ice crystals, such that ice 
preferentially initiates and grows 
in the aqueous external solution 
(i.e., the supporting culture medi-
um in cell therapies), providing the 
osmotic driving force for water to 
leave the intracellular environment 
and effectively shrinking the cells, 
which can be observed in real-time 
by cryomicroscopy [12].
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Cryoprotectants: solutes 
that enhance survival 
during freezing
Given this understanding of events 
during freezing, we can begin to 
understand the relevance of glycerol 
in Polge’s original successful experi-
ments [7], and the observations that 
over-wintering species frequently 
accumulate sugars or other poly-
ols [13]. It became clear that such 
solutes are structurally effective in 
hydrogen bonding, which in turn 
implies that they can interact in 
reversible ways to hydrogen bond 
with water molecules. This like-
wise imparts upon them proper-
ties to modulate ice formation on 
a kinetic basis, such that as cooling 
progresses, less ice is formed at a 
given sub-zero temperature, often 
to a greater degree than would be 
predicted from classical depression 
of freezing point effects of includ-
ed solutes. For example, starting 
in an isotonic culture medium (ef-
fectively close to 0.15M sodium 
chloride), salt concentrations will 
reach approximately 3.51 molal in 
the residual liquid fraction by freez-
ing to –5°C, whereas the presence 
of 1M cryoprotectant (CPA), such 
as glycerol, mitigates the rise in salt 
concentration such that even when 
freezing to below -30°C, less salt 
is present [10]. This process is de-
scribed in cryobiological terms as 
the colligative effects imparted by 
CPA. Glycerol was quickly applied 
to studies on freezing other import-
ant cell types, such as red blood 
cells for transfusion. In this era, 
Lovelock and Bishop described the 
freeze-modifying effects of dimtheyl 
suphoxide [DMSO], which equally 
acts in a colligative fashion, and has 
now become perhaps the most wide-
ly applied protective solute [14]. 
However, it should be noted that in 
both these (and subsequent cases), 
the CPA solutes need to be applied 
in concentrations far higher than 
for other solutes normally present 
in the cell media solutions, which in 
itself introduces complex biological 
challenges.  
The identification of these 
freeze-protecting solutes led by the 
1970’s to the term ‘cryoprotectant’ 
(or CPA) to be assigned to solutes 
that could enhance cell recovery, 
and an attempt to describe cryopro-
tectants in classical terms of phar-
macology [17]. A whole range of 
water-modifying agents were listed 
as CPA, but by the 1980’s the list 
of widely used CPA with good effi-
cacy had been refined down to ap-
proximately seven agents (Table 1). 
It became understood that some of 
the CPA (such as DMSO or glyc-
erol) would cross cell membranes 
and provide intracellular protec-
tion, whilst other agents such as 
sugars or polymers could provide 
CPA effects in cell systems where 
little intracellular permeation was 
taking place, which has been at-
tributed to their ability to produce 
partial dehydration and limit harm-
ful intracellular ice formation (see 
section below). This has led to the 
pragmatic classification of CPA as 
either cell-permeating or non-per-
meating agents [15]. Another im-
portant point is that CPA must also 
remain in solution at very low tem-
peratures during the cooling process 
– solutes that precipitate out at high 
subzero temperatures cannot effec-
tively modify ice formation during 
cryopreservation. Whilst wishing 
to avoid over-simplification, it is a 
‘rule of thumb’ that nearly all nucle-
ated mammalian cells require intra-
cellular protection during cryopres-
ervation; non-permeating CPA can 
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provide additional benefits to mod-
ulate ice crystal growth in the extra-
cellular environment (and thereby 
help mitigate the osmotic effects 
of ice formation), but they cannot 
normally provide primary cryopro-
tection [15]. This statement has to 
be moderated to some degree when 
considering cryoprotection afford-
ed by sugars such as trehalose and 
sucrose, which can be used to en-
tirely replace agents such as DMSO 
for some cell types; however, in this 
situation it is clear that the sugars 
are needed both extra- and intra-
cellularly, which can be achieved by 
pre-cryopreservation culture for 24 
hours [18,19]. Nevertheless, these 
additional effects of agents such as 
polymers and proteins should not 
be discounted when considering 
how to develop a CPA protocol for 
a given cell therapy, and can explain 
to some degree why for laboratory 
scale cryopreservation, many groups 
have used high protein concentra-
tions such as foetal calf serum in the 
freezing media in their cryobanking 
activities. 
It will be clear by now that CPA 
have important roles as water-mod-
ifying agents during freezing stress, 
but those same properties can cause 
problems for generalized cell func-
tion. Having high concentrations 
of a particular solute in the intra-
cellular environment will impact 
on almost all normal biological 
processes before or after cryopreser-
vation, and this interference can at 
some point become toxic, leading 
to cell injury even before ice forma-
tion. This is equally true in osmotic 
terms because, even though perme-
ating CPA may be chosen for use, 
they are needed in relatively high 
concentrations and they will take 
an identifiable time to cross the cell 
membrane, much slower than for 
water movement itself. Thus when 
exposing cells to CPA at concentra-
tions of 0.5M or above, there is an 
initial osmotic shrinkage of cells as 
water leaves, to be balanced by a cell 
volume re-equilibration as CPA and 
associated water molecules enter the 
intracellular space [20]. Transmem-
brane CPA permeation is largely a 
simple physico-chemical process, 
the kinetics of which mean that at 
ambient temperature for example, 
CPA permeation into mammalian 
oocytes as a model system requires 
some 10 minutes to approach equi-
librium [21]. The process is gener-
ally faster at higher temperatures, 
  f TABLE 1
Common cryoprotectant (CPA) identified by  widespread***, moderate**, or infrequent 
choice of agent.
Cell permeating agents Sugars (which may permeate 
cells to a degree depending on 
molecular size)
Polymers
Dimethyl sulphoxide*** Sucrose*** Polyethylene glycol (PEG)***
Ethylene glycol*** Trehalose*** Hydroxy ethyl starch***
Propylene glycol*** Raffinose** Polyvinyl pyrrolidone (PVP)**
Glycerol** Mannitol** Ficoll**
Methanol* Glucose* Serum proteins (mixture)**
Ethanol* Galactose* Milk proteins (mixture)**
Particular CPA mixtures are often selected for specific cell preservation strategies.  This list is not exhaustive and a wider discussion on 
CPA can be found in [15,16]. Oligosaccharides tend to act as non-permeating osmotically acting CPA, whereas monosaccharides may 
permeate mammalian cells to a degree depending on cell type.
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for example in mammalian cells 
cultured at 37oC, but higher tem-
peratures tend to exacerbate any 
chemical toxicities for the CPA. 
Low temperatures for CPA expo-
sure (such as 10oC or below) can 
mitigate chemical toxicity but also 
prolong exposure time to achieve 
good intracellular permeation, of-
ten by a factor of two or more [22]. 
Whilst some of these factors can be 
predictively modelled once variables 
such as cell membrane permeabili-
ty coefficients are known for water 
or CPA [23], there is currently no 
absolute substitute to performing 
prospective investigations to define 
the best CPA protocols to maintain 
good potency for specific cell ther-
apies during the cryopreservation 
process. Recently the application of 
algorithm-based objective optimis-
ation of cryoprotectant protocols is 
providing valuable information on 
these important areas for cell ther-
apy cryopreservation [24].            
The kinetics of cooling for 
successful cryopreservation 
and storage considerations
Successful cryopreservation was 
also found to be influenced by the 
kinetics of the cooling process it-
self. As often practiced today, slow 
cooling (where slow as a relative 
term applies to cooling rates of be-
tween about -0.3oC min-1 and -2oC 
min-1) were found by empirical ob-
servation to relate to good success. 
Mazur and colleague provided a 
hypothesis based on these obser-
vations, which he developed over 
many years [25]. It can be described 
as Mazur’s two-factor hypothesis 
and explained visually in Figure 1. 
To survive cryopreservation, cells 
are required to be optimally de-
hydrated to avoid intracellular ice 
formation; intracellular freezing 
was generally found to be associat-
ed with lethal cell injury in the vast 
majority of cases [26]. At an opti-
mal slow cooling rate, cells could 
be dehydrated with their sensitive 
molecular and ultrastructural com-
ponents protected by the added 
CPA. However, if very slow cooling 
(around -0.1oC min-1  or less) was 
instigated, cells were exposed to the 
extreme ice-related dehydration for 
intolerably long times, even in the 
presence of CPA, and again, lethal 
injury would ensue. This undoubt-
edly is an oversimplification of the 
complex biophysical processes oc-
curring during cryopreservation, 
many of which remain to be fully 
elucidated, but the two-factor hy-
pothesis does tend to fit the ob-
served outcomes in many cases over 
the intervening years. This is where 
the often quoted ‘-1oC min-1 cool-
ing rate’ has its origins; the ‘-1oC’ 
is not a mystical number, rather it 
is a reflection of the time required 
to achieve the optimal cell dehy-
dration for cell survival during the 
cryopreservation process. It is ex-
tremely important to understand 
that this is the safe cooling kinetic 
for the biomass itself when cooling 
cells, not just the cooling profile 
of the holding chamber, produced 
by whatever equipment is used to 
control cooling process. Controlled 
cooling can be provided by a num-
ber of cooling technologies based 
around liquid nitrogen vapour 
(e.g., Planer PLC; Cryomed™) or 
electrical Stirling Engine Systems 
(e.g., Asymptote PLC). In most 
cases, cooling small volumes in 
such equipment (such as tradition-
al 1.8  ml cryovials) will allow the 
vial contents to closely track the 
changing temperature conditions 
within the machine. However, clin-
ical scale cell therapies (discussed 
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below) often require cryopreserva-
tion at much larger volumes, where 
it is a much greater challenge to 
ensure that the biomass cools at 
appropriately survivable low rates 
(discussed below) because of the 
nature of heat and mass transfer in 
the large volumes.     
The question then arises as to what 
the desired end temperature should 
be for success, and the requirement 
for temperature control over that 
range. It has now been established 
from a number of studies that for 
true long-term stability, temperatures 
below -100oC become essential [27]. 
Cryobiology has provided informa-
tion on the physico-chemical status 
of the frozen matrix which indicates 
that in the range -120 to -130oC, a 
glassy transition occurs that finally 
and completely solidifies the mixed 
matrix of ice, solutes, CPA and bio-
mass in the samples. This tempera-
ture range relates to the total solute 
concentration of the mixture, but 
for all practical purposes in cell ther-
apy the quoted figures are relevant. 
It has been established empirically 
in different systems however, that 
practical benefits for slow cooling be-
yond about -60oC to -80oC are not 
 f FIGURE 1
Schematic of Mazur’s 2-factor hypothesis.
A cell with CPA protection subjected to cooling at different rates. Maximum functional recovery is achieved with an optimal cooling 
rate providing reversible dehydration occurring over the high subzero temperature range. If cooling is too slow, irreversible injurious 
dehydration can take place, for example the mitochondria and endoplasmic reticulum are structurally compromised. If cooling is too fast, 
cells do not have time to optimally dehydrate, and residual intracellular water can form ice, which is again injurious and can compromise 
structure of organelles. For many nucleated mammalian cells, ‘optimal’ cooling equates to rates of around -1oC min-1.  
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detectable, so cryopreservation pro-
tocols often terminate the imposed 
control of slow cooling at these 
temperatures [25,28]. Thereafter, the 
samples can be cooled below the glass 
transition to close to the storage tem-
perature in liquid or vapour phase 
nitrogen (for example to -160oC) 
at faster, pragmatically convenient, 
(but still controlled) rates of about 
-10o or -20oC min-1 [29]. Effectively 
by about -60oC, the residual solution 
in the sample, containing now high-
ly concentrated solutes and CPA, 
becomes so highly viscous that the 
glass transition event (Tg) becomes 
highly probable on further cooling. 
Within this matrix, the biomass is 
present as extremely dehydrated cells 
that contain no ice [30]. A schematic 
of a slow cooling process is provided 
in Figure 2. 
 f FIGURE 2
Steps in a slow cooling protocol.
Cells usually need permeation with CPA (green – top left) and often a secondary CPA (sucrose, orange), which is often achieved at 
temperatures between ambient to +4oC (top left). In many cases, a secondary CPA such as sucrose is added , which also starts cell 
dehydration. The mixture is cooled (red line) down to the ice nucleation temperature (often around -7oC) and ice nucleation starts 
(white icons). Active ice nucleation (called seeding) may be applied. A hold time (approximately 10 minutes depending on sample) can 
be introduced to allow dissipation of latent heat which may confound cooling control. Thereafter, slow controlled cooling produces 
responsive dehydration as ice crystal volume grows. This benefit of this is maximized by reaching approximately -50oC, and thereafter 
the sample can be cooled to below the glassy transition range (approx. -120oC) either at the same rate or more quickly (for practical 
considerations) and held in cryogenic storage. The cryopreserved sample thus comprises biomass (orange) and glassy matrix (grey 
blocks), mixed with ice already present.
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The value of liquid nitrogen as 
the storage medium of choice will 
be now be apparent because the 
temperature provided is far below 
that of the glass transition tem-
perature range, imparting a degree 
of safety to the process. The sta-
ble cryogenic temperatures (below 
-150oC) that can be obtained (with 
modern storage containers fitted 
with appropriate monitoring and 
if needed, autofill devices) are suf-
ficiently far enough below the glass 
transition range to yield true long-
term biopreservation on a scale 
probably greater than required for 
most cell therapies. It has been often 
discussed that below Tg and in the 
highly viscous environment, there 
is insufficient thermal energy for 
any chemical reactions or molecu-
lar diffusion to take place. The only 
potential harmful process to impact 
cryogenic storage has been suggest-
ed to be background ionising radia-
tion, and it has been estimated that 
it would take in excess of 104 years 
for cells at cryogenic temperatures 
to accumulate lethal injury [1]. In 
practical terms, there have been 
reports of cryopreserved cells, such 
as sperm or embryos, retaining nor-
mal functional processes after up to 
about 30 years cryo-storage [31,32]. 
Likely of more relevance to cell 
therapies, cells from umbilical cord 
blood have been used effectively af-
ter 11 years cryo-storage [33].
Historically, storage at -80oC us-
ing electrical freezers has been used 
for some cells such as red blood 
cells [34]. However, it will be clear 
from above discussions that storage 
above Tg is likely to result in slow 
but progressive cryo-attrition. In 
practical terms, a storage shelf-life 
has often been imposed. The FDA 
has approved -80oC storage of red 
blood cells for 10 years [35]. For 
more complex systems, storage at 
-80oC for prolonged periods may 
be more problematic for exam-
ple, in work on liver cell spheroid 
cryo-storage it was shown that sig-
nificant cryo-attrition occurred over 
1 year of storage [36]. For each cell 
therapy, the ease of application for 
storage at -80oC needs to be bal-
anced by an understanding of prod-
uct stability. The advent of electrical 
freezers operating in the -120oC 
range has opened this possibility as 
a storage temperature for cell ther-
apies, which is predicted to have 
successfully long storage times, but 
little published information on that 
is currently available for prospective 
studies comparing these technolo-
gies with liquid nitrogen storage.  
Given the expected stability of 
storage below Tg, the occasional 
report on negative effects of storage 
duration [37] are difficult to under-
stand on a physico-chemical basis. 
However, during practical storage 
of cell products, there is always a 
potential for fluctuations in storage 
temperature if cryogen levels are al-
lowed to vary widely (e.g., during 
intermittent delayed times of filling 
with liquid nitrogen) or if samples, 
held in racks or trays, are removed 
from storage whilst accessing specif-
ic products on day of requirement. 
Even though the products may ap-
pear visibly ‘deep frozen’ during 
this process, it has been shown that 
significant temperature upshift (e.g. 
from -135oC to -60oC) could occur 
within a few minutes of lifting racks 
out from storage [38]. Repeated tem-
perature cycling through the range 
for Tg in this fashion led to a de-
crease in cell functional recoveries. 
The choice of storage in liquid or 
vapour phase nitrogen for cell ther-
apies has trended towards vapour 
phase storage. The possibility of 
CELL & GENE THERAPY INSIGHTS 
368 DOI: 10.18609/cgti.2017.038
transfering infectious agents found 
in commercially produced liquid 
nitrogen has been discussed and 
experimentally demonstrated [39]. 
Vapour phase storage (with tem-
peratures usually in the region of 
-150o to -170oC) is attractive, but 
potentially capable of rapid tem-
perature fluxes such as when open-
ing the storage container. Happily, 
the placement of commonly used 
aluminium racks within the storage 
tank acts as a ‘cold sink’ to stabilise 
the internal environmental tem-
perature, and this can be further 
stabilised by simple processes such 
as adding a copper fin [40] within 
the storage tank.  For optimal stor-
age of cell therapies, cryo-bank ac-
cess procedures should be subject to 
protocol management and routine 
data record.  
Considerations for warming  
For successful recovery of potent 
cell therapies, the reversal of all the 
above described biophysical events 
has to be performed in ways which 
do not compound injury. For the 
most part, cell therapies are tradi-
tionally subject to cooling, in the 
presence of significant ice content 
in the sample. It has long been rec-
ognised that during the warming 
process, existing ice crystals may 
undergo ice crystal growth and 
re-organisation (known as Ostwald 
ripening), which may impart fur-
ther injury depending upon the 
kinetics of the process [41]. In addi-
tion, if small intracellular ice nuclei 
were established during the cool-
ing process, but did not grow to 
become injurious, these may grow 
during warming, again depending 
on the kinetics of warming, such 
that ‘freezing during thawing’ can 
be conceptualised [42]. For these 
various reasons, fast warming has 
traditionally been favored [9,43]. 
In fact, for slowly cooled cryopre-
served cells, the impact of warming 
kinetics is complex and not easy 
to predict. It has been alternative-
ly argued that slow warming may 
be beneficial to allow time for os-
motic re-equilibration processes 
to take place [25] when the highly 
shrunken cells start to encounter 
more liquid water as the ice matrix 
melts at high subzero temperatures. 
In some experiments on particular 
cell types, the impact of slow versus 
fast warming was either not signifi-
cant or was related to the particular 
CPA used [44]. This raises another 
potential warming factor – expo-
sure of the cells to toxic high CPA 
concentrations at high subzero tem-
peratures during slow warming. 
Warming is an area which deserves 
greater future investigation. As in 
cooling, terms such as ‘fast’ or ‘slow’ 
warming are relative and should be 
defined in any cell therapy protocol 
for process repeatability.    
Cryopreservation and cell 
product potency
In many cases, the potency of thawed 
cell therapies may not equate to 
what might be predicted from the 
doses selected for cryopreservation. 
It has been known for some time 
that a series of sublethal stresses can 
accumulate in the cells during the 
multiple steps of cryopreservation, 
and may only be expressed gradually 
after rewarming in a process known 
as ‘cryopreservation cap’ or ‘cryo-
preservation-induced delayed onset 
cell death’ [45,46]. Cell death path-
ways such as apoptosis and necrosis 
have been identified. There appears 
to be a progression of expressed 
injury over the first 12–24 h post-
thaw, and subsequently surviving 
cells may resume normal function 
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including cell division [29]. Target-
ed molecular strategies have been 
suggested to mitigate against these 
injuries [47] but for clinical applica-
tion these need to be regulatory ap-
proved strategies. These post-thaw 
injury markers also offer one way 
to audit effectiveness of cryopreser-
vation protocols or assess protocol 
change.  
Cryogenic preservation 
in the absence of ice: 
vitrification
The concept that biological cryo-
preservation could be achieved 
by avoiding ice injury with pro-
cesses that entirely inhibit crystal 
growth has been considered for 
many years; the original paper by 
 f FIGURE 3
A stylized liquidus curve for a notional CPA, showing the physical states achieved as cooling proceeds.
The initial aqueous sample can be viewed as an amorphous liquid for this purpose.  At low starting CPA concentrations (say <20%), slow 
cooling (to the right of the image) produces ice (white icons)) plus liquid and residual liquid. As slow cooling proceeds and more ice is 
produced, the relative concentration of CPA in residual liquid increases (to the right of slow yellow curve), until increased concentration 
and decreased temperature drive the glassy transition (Tg). Tg occurs at higher subzero temperatures if higher CPA concentrations are 
used. It is possible to cool to a stable Tg using very high (>80%) CPA, but these are invariably cytotoxic. In practical cell cryopreservation 
by slow cooling, ice plus glassy matrix co-exist beyond approximately -120oC.  During warming, devitrification (dashed yellow lines) tends 
to occur  at lower temperatures with lower CPA, and ice crystals can grow. For ultra-rapid cooling (left side box, red), amorphous matrix 
is preserved from above 0oC throughout the cooling, at rates greater than -1000oC min-1 to reach Tg  (dashed red curve) but this tends 
to be metastable with similar problems of devitrification on warming. The figure is a simplification of events for visual presentation; for 
details see Muldrew (2004), Fahy & Wowk (2015).
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Polge and colleagues [7] used the 
term ‘vitrification’ to denote that 
something unusual was happen-
ing which allowed sperm survival 
(although their system does not 
match up with what we understand 
by ‘vitrification’ today). At around 
the same time, Luyet and Gehen-
io made observations of an ice-free 
solidification of protoplasm which 
required ultra-rapid cooling (sev-
eral thousand oC min-1) [6]. Later, 
Rall and Fay were able to translate 
the ideas into an achievable tech-
nology for successful cryogenic 
preservation of mouse embry-
os [48]. Vitrification as currently 
practiced requires very high con-
centrations of CPA (as much as six 
times those used in traditional slow 
cooling cryopreservation), which 
cells can only tolerate for short pe-
riods (usually seconds of exposure 
time) before they become toxic, 
and thus still requiring rapid cool-
ing and warming (which in turn 
limits the volumes used to <1 ml). 
This combination of factors allows 
Tg of the system to be reached 
whilst suppressing ice crystal for-
mation. Much has been learned 
about the biophysics underpin-
ning vitrification [49], and Figure 3 
depicts the important biophysical 
characteristics. The technology has 
recently become widely applied in 
reproductive cryo-banking for in-
fertility treatment [50]. However, 
because of the volume limitations, 
vitrification has not yet been de-
veloped into technologies for what 
might be considered more general 
cell therapy cryo-banking. Recent 
studies have been made into devel-
opment of vitrification technolo-
gies compatible with large volumes 
(see Puschmann et al [51] for a re-
view), but these have yet to be ap-
plied to deliverable cell therapies. 
APPLICATIONS OF CRYO-
PRESERVATION FOR CELL 
THERAPIES & CHALLENGES 
FOR ROBUST PRODUCT 
DELIVERY
Historical and current cell 
therapy cryopreservation
Cryopreservation of bone mar-
row-derived hematopoietic pro-
genitor cells (HPC) is an example 
of a cell therapy product which 
has been applied widely since the 
1960s [52,53]. The principles of slow 
cooling cryopreservation (around 
-1oC min-1), with DMSO at 10% 
w/v as CPA and storage at either 
-80oC or, less than -130oC have 
been routinely used [54]. Using sec-
ondary CPA such as hydroxyl eth-
yl starch has allowed reduction of 
DMSO to 5% concentrations, with 
hydroxyl ethyl starch added at 6% 
w/v [55]. Special cryopreservation 
bags (e.g. Miltenyi Biotec or Maco-
Pharma) with a range of fill volumes 
up to 250 ml allow maintenance of 
suitable cooling profiles and good 
warming rates when immersed in 
a waterbath at 37oC [56]. Post-thaw 
manipulation of HPC has often 
been avoided by direct transfusion 
of the thawed cell product, but this 
can occasionally lead to patient-re-
lated adverse events [54]. Some au-
thors developed washing procedures 
to dilute CPA before infusion, as a 
way to reduce any patient-related 
adverse events following infusion of 
DMSO, with acceptable cell prod-
uct survival [57].  
As other cell therapies have en-
tered the arena within the broad 
area of hematopoietic stem cell 
replacement, slow cooling cryo-
preservation has maintained its 
beneficial role, but with some ad-
dition to detail in terms of protocol 
management. For example, when 
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cryopreserving umbilical cord 
blood, Woods and colleagues [58] 
and Hunt et al [59] investigated 
steps to limit CPA toxicities when 
applying DMSO. There have been 
several reports of mesenchymal 
stromal cells for expansion and 
cryopreservation for clinical appli-
cations, such as in graft versus host 
disease [60], but the product poten-
cy has come into question [61] and 
cryopreservation was one of the 
steps under scrutiny. Further de-
tailed studies indicated a range of 
reversible and non-reversible effects 
of cryopreservation in mesenchy-
mal stromal cells using slow cooling 
with a range of DMSO concentra-
tions and cell pre-treatments [62]. 
Post-thaw culture for 24  h was 
found to be effective in reparation 
of many of the cryo-induced abnor-
malities. A recent review of cryo-
preservation practices across UK 
centres applying slow cooling cryo-
preservation for peripheral blood 
stem cells identified differences in 
practices which were reported un-
der the umbrella term ‘cryopreser-
vation’ [63]. These combined studies 
highlight an important point for all 
cell therapy cryopreservation activ-
ities; this is that cryopreservation is 
not a simple ‘standardised one op-
tion’ process, the various protocol 
steps need to be well documented 
in standard operating procedures, 
and the equipment involved should 
be applied with care and monitored 
frequently against documented per-
formance criteria. The authors also 
cautioned that straightforward as-
says of cell viability post-thaw may 
not correlate well with other more 
exacting tests of product poten-
cy, which again is something that 
needs to be part of protocol testing 
and audit for any cell therapy cryo-
preservation practices.   
With the recent arrival of manip-
ulated T cell therapies, such as chi-
meric antigen receptor engineered 
(CAR ) T cells destined for autolo-
gous transfusion [64,65], cryopreser-
vation will undoubtedly remain the 
important facilitatory technology in 
the pathways for product manage-
ment, batch safety and potency val-
idation, and, in many cases, deliv-
ery to end users. Cryopreservation 
has already been discussed in these 
terms [64] but cryo-protocol details 
are as yet sparsely reported and it is 
likely that general slow cooling re-
gimes originally developed for HPC 
have been adopted. Here also, prod-
uct depletion and post-thaw poten-
cy have been reported [66]. Other 
manipulated allogeneic immune cell 
therapies (such as natural killer cell 
or regulatory T-lymphocyte thera-
pies) face the same requirement for 
cryopreservation to meet ‘off the 
shelf ’ product delivery, but again 
post-thaw attrition in cell respons-
es has been highlighted [67]. There 
is an opportunity for much further 
work on fundamental cryobiology 
and translational cryopreservation 
research in the CAR-T cell arena 
to improve potency. In the short 
term, it may be possible to mitigate 
against loss of potency post-thaw 
by adjusting dose (delivered cell 
numbers) but this still leaves diffi-
cult questions if the impact of cryo-
preservation on the therapeutic cell 
population is not fully understood, 
and which may therefore vary be-
tween batches. 
Challenges for scale up for 
large volume cell therapies 
In the discussions so far, cryopres-
ervation has been applied to single 
cell products at a scale very similar 
to those used traditionally for hae-
matopoietic stem cells. In other 
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areas, larger cell therapy volumes 
are required, e.g., cell therapy for 
organ support such as the bioarti-
ficial liver where multicellular units 
in volumes of between 1–2 litres 
are required at clinical scale [68]. A 
potential difference in approach to 
cryopreservation for multicellular 
products (such as cell spheroids) 
under consideration is the impact 
of controlling ice nucleation during 
slow cooling. We have discussed the 
fact that optimal cryo-dehydration 
is essential for cell survival, which 
is achieved by the osmotic effects 
of the growing ice content in the 
sample. This implies that ice crys-
tal initiation should be a repeatable 
process during cooling to achieve 
a standardised process, but ice nu-
cleation is a stochastic event, and 
on any one cooling run can occur 
unpredictably at different tempera-
tures far colder than the equilibri-
um melting temperature of the mix-
ture (where ice would first be able 
to co-exist with liquid) in different 
samples [69]. Controlled ice nucle-
ation can be achieved by momen-
tary application of a cold metal rod 
to the outside of a container such 
as a cryo-vial in the process known 
as ‘ice seeding’ and has become 
routine in reproductive cryopreser-
vation where there are only a small 
number of samples per run [70]. 
This is a physical event, whereby 
local deep cooling applied to the 
surface of the container produces 
ice crystals on the inside wall – it 
has to be visually checked that ice 
is present internally in the vial and 
not just ‘frosting’ on the external 
surface. Ice nucleation can also be 
induced across a group of vials be-
ing slowly cooled together by intro-
ducing a brief ‘shock cool’ step with 
rapid cooling in the cryo-cooler for 
approximately 2 minutes [71,72] 
before returning to the pro-
grammed slow cooling protocol. 
Organisation of water molecules 
into ice nuclei can also be achieved 
by certain types of physico-chemi-
cal surface properties, (often termed 
ice nucleating agents) for example, 
crystalline cholesterol, included 
in the CPA mix, and providing a 
more reproducible cell cryo-de-
hydration and often increased cell 
recoveries [29]. Other types of in-
organic ice nucleating surfaces are 
under development [IceStart™, As-
ymptote]. Another problem with 
cryopreservation of large samples is 
maintaining consistent heat transfer 
throughout the sample volume for 
homogenous cooling, since cooling 
devices work by surface cooling, 
which depends on the heat trans-
fer properties of the container and 
the cell mixture [73]. The appro-
priate placement of thermocouples 
in sample containers during exper-
imental cryo-cooling runs allows 
assessment of differences between 
different sample compartments, or 
individual samples, and the cooling 
device chamber [29,73]. Any differ-
ences can be mitigated by altering 
the cooling programme if required. 
The desired control of cooling can 
be further disrupted by the release 
of latent heat of ice nucleation deep 
within large aqueous volumes [74]. 
Alterations of the cooling ramp 
of the cooling machine, such that 
heat extraction is maximised over 
a particular but defined range of 
temperatures where the latent heat 
effect predominates is one way to 
improve overall sample cooling 
profiles [30]. 
When considering warming rates 
for larger cryopreserved volumes, 
similar concerns exist about ho-
mogenous heat transfer; the usual 
process of immersing cryopreserved 
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samples in a warming bath may 
leave core volumes in a frozen 
state for extended periods and not 
achieving the desired rapid warm-
ing profile [73,74], thereby expos-
ing cells to CPA at potentially toxic 
temperatures. Warming is one area 
of cryopreservation that requires 
much further study, and under-
standing the interactions between 
optimal cooling and warming pro-
files to maximise cell recovery and 
potency could benefit from this.
Commercially available contain-
ers (cryo-bags) enable cryopreserva-
tion of biomass up to volumes of ap-
proximately 250 mL and are filled to 
a recommended volume to produce 
a sample height of less than 5 mm. 
This thin envelope configuration 
ensures that the contents of the bag 
are cooled homogenously; the rela-
tive thinness of the bag also facili-
tates fast warming rates. However, 
the dimensions of the current cryo-
bags cannot sustain volumes greater 
than 250 mL whilst maintaining 
less than 5 mm height. Increasing 
the height of the bag compromises 
the heat transfer process and creates 
a temperature gradient within the 
biomass. At volumes greater than 
250  ml, maintaining the height at 
less than 5 mm requires a bag with 
impracticable dimensions (length 
and width) to freeze with the cur-
rent accessible technology (i.e., con-
trolled rate freezers). Therefore, the 
design of the cryo-container is also 
a factor under careful consideration 
when cryopreserving large volume 
cell therapies, as it must support 
the homogenous freezing and thaw-
ing kinetics of the biomass. 
Another important key aspect for 
successful cell therapy is the quick 
recovery of the biological con-
structs after cryopreservation in a 
relevant time frame for immediate 
availability to the patients. Similar 
to the production process, recovery 
could be achieved by transferring 
these cell constructs into a biore-
actor which provides a dynamic 
environment aiming to mimic the 
perfusion condition which cells are 
subjected to in vivo, with more ef-
fective mass transfer properties [75]. 
A number of different types of bio-
reactors exist (fluidised bed, rotary 
cell culture system) that can op-
timally support cell recovery and 
metabolism whilst minimising cell 
damage [76–79]. Such systems can 
be readily scaled-up for fast recovery 
of large volumes of cryopreserved 
cell therapies.
Cell encapsulation within hy-
drogels is widely used in some 
cell-based therapies, as biocom-
patible materials can isolate ther-
apeutic cells from the host, avoid-
ing rejection, providing a physical 
support, and allowing a controlled 
release of cells from biodegrad-
able materials. The process of 
encapsulation typically uses liq-
uid precursors that become solid 
upon polymerization or polymer 
chain crosslinking. Cryopres-
ervation of encapsulated cells 
must ensure maintenance of the 
chemical structure and physical 
characteristics of the biomaterial 
as they greatly influence cell be-
havior and may potentially affect 
the outcome of the therapy. Sev-
eral studies have shown promising 
protective effects of biomaterials 
on cell cryopreservation [80]. In a 
more mechanistic study, alginate 
hydrogel was shown to inhibit de-
vitrification during the warming 
process of vitrified stem cells [81]. 
Altogether, these beneficial prop-
erties make encapsulation an en-
couraging strategy for cell therapy 
and the cryopreservation process.
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Considerations for GMP 
transfer of cell therapy cryo-
preservation technologies
Moving cell therapy cryopreser-
vation to clinical application will 
predictably require maintenance of 
the same GMP-aligned steps that 
are important across the whole 
cycle for product delivery. All pre- 
and post-cryopreservation product 
manipulations must be performed 
in ways that adhere to regulatory 
requirements, using media formu-
lations, CPA additives, containers 
(such as cryo-bags), cryo-cooling 
equipment, identifying labelling 
and traceability documentation, 
storage temperature monitoring 
and product delivery systems; all of 
equal importance [1]. The value of 
producing a comprehensive quali-
ty programme for a cryopreserved 
cell therapy (in this case periph-
eral blood mononuclear cells) has 
been discussed by Ducar and col-
leagues [82]. DMSO has so far been 
the most widely used CPA, which 
must be of highest quality and endo-
toxin-free. One point of discussion 
has been the use of regulatory-com-
pliant protein sources (such as foetal 
bovine serum or human serum) [83] 
or xeno-protein free solutions [84] 
as a CPA carrier media. Some 
commercially available GMP-com-
pliant CPA solutions have recent-
ly become available (CryoStor™, 
BioLife) [2]. For specific types of 
non-autologous cell therapies, the 
importance of recording and testing 
of cell provenance throughout the 
development of master and working 
cell banks is an additional import-
ant consideration [85]. 
A number of options are avail-
able for cooling equipment when 
applying controlled slow rate 
cryopreservation. Passive cooling 
devices may be suitable for small 
volumes and sample numbers of a 
particular product type, such as Mr 
Frosty™ (Thermo Fisher Scientific) 
or CoolCell®, (Biocision). Equip-
ment capable of handling larger 
volumes or more exacting cooling 
profiles are available based on liq-
uid nitrogen technology (Planer 
PLC; Cryomed™) or electrical Stir-
ling engine principles (Asymptote 
Ltd).  The importance of under-
standing the true sample cooling 
profile (which can be audited by a 
recording system in a dummy vial) 
as opposed to the selected chamber 
program has already been discussed 
above [29,74].  For storage, filling 
and cryogenic transportation of 
cell therapy products, a number of 
companies provide a range of regu-
latory compliant options [Panason-
ic; Thermofisher Scientific; Praxair; 
Thames Cryogenic]. Liquid nitro-
gen is not a sterile product unless 
specifically treated, and thus proto-
cols for handling and storage need 
to be developed that avoid compro-
mising GMP environments [39,86]. 
Since nitrogen vapour can deplete 
room oxygen levels, air oxygen 
monitors are required where the liq-
uid nitrogen is located and handled 
as part of general risk assessments 
and safety measures, which also in-
clude personal safety equipment to 
avoid ‘cold injury’ from accidental 
contact with the cryogen [87].  
Technical innovations continue 
to come on stream to make cryo-
preservation more robust in the 
context of regulatory oversight for 
delivering cryo-banked cell thera-
pies. Labelling systems that survive 
cryogenic exposure are provided by 
a range of companies (GA Interna-
tional; Biosafe). Thawing devices 
capable of imposing and recording 
warming profiles for cryopreserved 
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product in either cryo-vial or cryo-
bag formats are now available (Med-
cision™; Asymptote). Secure closure 
vials and automatic fi ll systems 
can meet the demands for some 
cell therapies (e.g. Cook Regentec; 
Wheaton®). Lyophilisation (freeze 
drying) with ambient storage is 
being developed as an additional 
biopreservation strategy for some 
nucleated cell products (Lyotech-
nology, Osiris Th erapeutics Inc.). 
A number of companies are devel-
oping sophisticated cryo-product 
management systems and cloud-
based information repositories that 
will help drive up standards of best 
practice and information sharing 
between organisations. Much infor-
mation in these areas of cryopres-
ervation is available via specialist 
academic societies such as the In-
ternational Society for Cryobiology 
and International Society for Stem 
Cell Th erapy.    
TRANSLATIONAL INSIGHT
Cryopreservation of cell therapies 
is an important part of product 
delivery and process management. 
When optimally applied, it can also 
reduce costs by avoiding wastage of 
product which would otherwise be 
‘out of shelf life’. However, there 
remains a signifi cant opportunity 
to improve application of the cryo-
preservation process itself by con-
tinued research into both funda-
mental and applied cryobiology. As 
diff erent, novel, or large-scale cell 
therapies come on stream, they will 
likely require improved approaches 
to cryogenic preservation.
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